临床荟萃

• 论著 • 上一篇    下一篇

恩度联合顺铂对老年肿瘤患者恶性腹水的疗效

  

  1. 1.河北医科大学第四医院 肿瘤内科,河北 石家庄 050011;2.沧州市中心医院 肿瘤科,河北 石家庄 061000;
    3.河北医科大学 a.流行病与统计学教研室; b.门诊部, 河北 石家庄 050000
  • 出版日期:2020-02-20 发布日期:2020-03-24
  • 通讯作者: 贾金海,Email: 807210221@qq.com
  • 基金资助:
    河北省医学科学研究重点课题计划----磷酸化组蛋白H2AX与胃癌早期诊断的研究(20100033)

Effect of endostatin combined with cisplatin on elderly cancer patients with malignant ascites

  1. 1.Department of Medical Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China;
    2.Department of Oncology, Cangzhou Central Hospital, Cangzhou 061000, China; 3a. Department of
    Epidemiology; b.Department of Outpatient,  Hebei Medical University, Shijiazhuang 050017, China
  • Online:2020-02-20 Published:2020-03-24
  • Contact: Corresponding author: Jia Jinhai, Email: 807210221@qq.com

摘要: 目的  采用腹腔给药的方式观察恩度联合顺铂对老年人难治性恶性腹水的临床疗效,生活质量的改善及免疫力的影响。方法  收集经病理确诊的恶性腹腔积液老年患者64例。持续引流后,对照组:顺铂30 mg腹腔注射d1、d4、d7;21天重复,联合用药组(试验组):顺铂30 mg +恩度45 mg腹腔注射d1、d4、d7;21天为一疗程。两组均完成2个同期的治疗。通过实体瘤的疗效诊断标准(RECIST)评价两组临床疗效,通过美国国立癌症研究所(NCI)标准评价不良反应;通过心理问卷评估对患者焦虑、抑郁的改善,抽取静脉血,监测治疗前后CD4/CD8水平。 结果  试验组临床有效率高于对照组,显著改善了患者的焦虑及抑郁状态;试验组较对照组并未显著降低CD4/CD8。结论  恩度联合顺铂提高腹水缓解率,未增加明显不良反应;改善焦虑抑郁状态;未降低患者的免疫力。

关键词: 腹水, 恩度, 顺铂, 腹腔给药, 老年人

Abstract: Objective  To adopt intraperitoneal  administration and observe the control group(Cisplatin) and combination group(endostatin combined with cisplatin)in order to see the effects on elderly patients with malignant ascites in clinical efficacy,  the improvement of life quality and immunity.Methods  Totally sixtyfour elderly patients diagnosed with malignant ascites were collected. And they were divided into control group and combination group. Patients in control group were given 30 mg of cisplatin  by intraperitoneal  administration on day 1,  day 4,  day 7,  respectively. And one cycle of treatment was  21 days. Patients in combination group were given 30 mg of cisplatin  and 45 mg of  endostatin (Endostar)  by intraperitoneal administrationon day 1,  day 4,  day 7,  respectively. And one course of treatment was 21 days. All  patients in two groups were treated for two cycles. The efficacy evaluation criteria(RECIST)was used to evaluate clinical efficacy of  two groups,  and the side effects were evaluated by NCI. The improvement of anxiety and depression was evaluated by psychological questionnaire,  and the level of CD4/CD8 was monitored before and after treatment.Results  The efficacy of  experimental group was higher than that of  control group,  which significantly improved the anxiety and depression of the patients; the CD4/CD8 of  experimental  group was not significantly lower than that of  control group. Conclusion  Endostar  combined with cisplatin can improve the remission rate of ascites without obvious side effects,  and they can also improve the state of anxiety and depression without reducing the immunity of patients.

Key words: ascites;endostatin; , cisplatin;  , intraperitoneal administration, aged